Amphastar Pharma Revenue, Profits - AMPH Quarterly Income Statement

Add to My Stocks
$15.77 $0.33 (2.05%) AMPH stock closing price Jun 22, 2018 (Closing)

AMPH stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Amphastar Pharma stock price. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 60.4M to 58.39M and how operating and non operating activities have impacted the AMPH stock. One also needs to look at Amphastar Pharma assets, operating expenses and Amphastar Pharma free cash flow. The Amphastar Pharma profit and loss statement shows revenue of $58.39M for 2018 Q1. Revenue has decreased by -3.33% QoQ for AMPH stock.

View and download details of revenue and profits for Amphastar Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Amphastar Pharma Revenues or Net Sales
58.39M60.4M57.92M65.19M56.67M63.54M64.22M68.03M59.37M76.91M
Cost Of Goods Sold (COGS)41.33M39.83M37.27M38.44M33.84M43.59M36.61M36.31M34.46M43.75M
Amphastar Pharma Gross Profit
17.06M20.59M20.64M26.74M22.82M19.96M27.61M31.71M24.9M33.18M
Research & Development Expense14.26M11.39M10.04M10.73M11.25M12.61M9.72M10.48M8.38M8.67M
Selling General & Admin Expense12.71M10.85M13.42M13.83M10.17M11.87M12.09M10.9M12.43M10.16M
Income Before Depreciation Depletion Amortization-9.91M-1.65M-2.82M2.18M1.4M-4.5M5.79M10.33M4.07M14.37M
Depreciation Depletion Amortization----------
Non Operating Income--1.09M1.22M--0.06M--0.27M--3.82M
Interest Expense----------
Amphastar Pharma Pretax Income
-9.03M-1.06M-1.99M3.17M1.5M-4.62M6M9.75M3.81M10.32M
Provision for Income Taxes-1.78M-2.53M-2.16M1.2M--1.87M2.11M2.85M1.32M2.8M
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-7.25M1.47M-1.97M--2.74M3.89M6.9M2.49M7.53M
Extraordinary Items & Discontinued Operations----------
Amphastar Pharma Profit/ Loss (Net Income)
-7.25M1.47M-1.97M--2.74M3.89M6.9M2.49M7.53M
Average Shares used to compute Diluted EPS46.51M49.33M48.22M47.87M48.06M46.1M47.95M45.97M46.81M46.71M
Average Shares used to compute Basic EPS46.51M46.23M46.1M46.03M46.07M46.1M45.4M44.96M45.04M45.09M
Income Before Nonrecurring Items-2.45M4.8M3.5M5.43M1.39M-2.74M3.89M6.15M3.04M7.76M
Income from Nonrecurring Items-4.79M-3.33M-3.32M-3.46M-0.5M----0.55M-0.23M
Amphastar Pharma Earnings Per Share Basic Net
-0.160.030.000.040.02-0.060.090.150.060.17
Amphastar Pharma Earnings Per Share Diluted Net
-0.160.030.000.040.02-0.060.080.150.050.16
EPS Diluted Before Nonrecurring Items-0.050.100.070.110.03-0.060.080.140.060.16
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Amphastar Pharma stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that AMPH stock has a topline or revenue of $58.39M for 2018 Q1 as per this Amphastar Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: Most businesses like Amphastar Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the AMPH income statement, one can check the Amphastar Pharma historical stock prices to check how the price has moved with time.

Amphastar Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
3.17
Dividend Yield
0%